Roche Holding and Atea Pharmaceuticals have joined forces to develop an antiviral oral treatment called AT-527, now in phase 2 clinical trials, as a potential treatment for COVID-19 patients, the companies said on Thursday.
If the pill is approved, Boston-based Atea will distribute it in the United States and Roche will be responsible for global manufacturing and
distribution outside the U.S. market. Atea will get an upfront payment of $350 million in cash from Roche with potential for future milestone payments and royalties.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
This Teen's Discovery of a Protein-Binding Molecule Could Lead to a COVID-19 CureAnika Chebrolu from Frisco, TX, won the 2020 3M Young Scientist Challenge for pinpointing a molecule that could lead to a potential cure for COVID-19.
Read more »
National Well-Being Before and During the PandemicHow is the pandemic affecting our well-being? Take a look at these 6 key life areas to see where people are flourishing—and what needs some work, writes HFHarvard
Read more »
Rapid Test Results May Go Unreported, Officials SayWith a growing number of COVID-19 rapid tests available, the U.S. can test millions of people each day, but many of the results may be unreported, according to The Associated Press.
Read more »
University of Arizona students asked to minimize holiday travel to stem COVID spreadThe University of Arizona has reported at least 2,433 COVID-19 infections among students and staff.
Read more »
Coronavirus Disease 2019 (COVID-19)Don’t let safety take a holiday 🧳. Follow these updated CDCgov guidelines to make sure you are safely celebrating the holiday season during COVID19:
Read more »